Relief Therapeutics Holding SA
SIX:RLF
Relief Therapeutics Holding SA
Inventory
Relief Therapeutics Holding SA
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Inventory
CHf923k
|
CAGR 3-Years
56%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Inventory
$4.2m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Inventory
CHf21.6m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
8%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Inventory
CHf86m
|
CAGR 3-Years
66%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Inventory
CHf13.7m
|
CAGR 3-Years
80%
|
CAGR 5-Years
62%
|
CAGR 10-Years
N/A
|
|
Relief Therapeutics Holding SA
Glance View
RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company. The company is headquartered in Geneve, Geneve and currently employs 55 full-time employees. The company went IPO on 2011-09-19. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. The company specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The firm is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.
See Also
What is Relief Therapeutics Holding SA's Inventory?
Inventory
923k
CHF
Based on the financial report for Jun 30, 2025, Relief Therapeutics Holding SA's Inventory amounts to 923k CHF.
What is Relief Therapeutics Holding SA's Inventory growth rate?
Inventory CAGR 3Y
56%
Over the last year, the Inventory growth was 147%. The average annual Inventory growth rates for Relief Therapeutics Holding SA have been 56% over the past three years .
